BPC-157 vs TB-500
BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric protective protein, while TB-500 is a synthetic fragment related to thymosin beta-4. Both are studied for tissue-support and recovery contexts in published research. Neither is FDA-approved; clinicians evaluate appropriateness on a case-by-case basis.
What's being compared
Synthetic fragment related to the thymosin beta-4 protein.
Side-by-side comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Derived from a sequence within human gastric juice protein BPC. | Synthetic fragment related to the actin-binding protein thymosin beta-4. |
| Mechanism in research | Studied for effects on angiogenesis, tendon and ligament fibroblast signaling, and gut-mucosal pathways. | Studied for actin sequestration and cell migration relevant to tissue repair. |
| Common research applications | Tendon, ligament, and gastrointestinal tissue support contexts in animal and pre-clinical literature. | Soft-tissue, vascular, and recovery contexts in animal and pre-clinical literature. |
| Routes discussed in literature | Subcutaneous and oral routes appear in the published literature. | Primarily subcutaneous in published research; intramuscular is also discussed. |
| Reported half-life context | Short systemic half-life; local tissue effects discussed in research. | Longer reported circulating presence than BPC-157 in animal data. |
| Regulatory status | Not FDA-approved as a finished product. Compounded availability depends on pharmacy and clinician determination. | Not FDA-approved as a finished product. Compounded availability depends on pharmacy and clinician determination. |
| Evidence base | Largely pre-clinical (animal and in-vitro) literature; published human studies are limited. | Largely pre-clinical literature on the parent thymosin beta-4 protein; published human studies are limited. |
| Typical clinician use case | Considered by clinicians in tendon, ligament, and gut-mucosal contexts as a clinician-directed compounded preparation. | Considered by clinicians in soft-tissue and vascular recovery contexts as a clinician-directed compounded preparation, often paired with BPC-157. |
| Clinician evaluation | Clinician evaluation considers history, prior tissue work, and individual response context. | Clinician evaluation considers history, prior tissue work, and individual response context. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
BPC-157 is the more frequently discussed of the two for those tissue contexts in published research.
TB-500 is the more frequently discussed of the two in actin-related and vascular research contexts.
Some clinicians consider a combined protocol (the Regen Therapy RT-02 protocol pairs BPC-157 with TB-500) when individually appropriate after evaluation.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Are BPC-157 and TB-500 the same kind of peptide?
No. BPC-157 is derived from a sequence in a human gastric protein, while TB-500 is a synthetic fragment related to thymosin beta-4. They have different mechanisms and different research literature.
Are BPC-157 or TB-500 FDA-approved?
Neither is approved by the FDA as a finished pharmaceutical product. Any compounded availability is on a patient-specific prescription after a clinician evaluation.
Can BPC-157 and TB-500 be used together?
Some published protocols and clinician-directed compounded preparations pair the two. Whether that combination is appropriate is a clinical decision made on a per-patient basis.
How are these typically administered?
Subcutaneous injection is the most common route discussed in the literature for both. BPC-157 also appears in oral preparations in some research contexts.
What does Regen Therapy offer in this category?
The RT-02 tissue-support protocol pairs BPC-157 with TB-500 as a clinician-directed compounded preparation, dispensed by Wells Pharmacy Network when clinically appropriate after evaluation.
How do clinicians decide between them?
It depends on the individual situation, prior history, the tissue context being addressed, and the clinician's interpretation of the available research. There is no one-size-fits-all answer.